EVNIN LUKE sold $45K of HOWL (indirect holdings)

EVNIN LUKE sold 143,199 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.31 ($0.31–$0.32) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published Jul 8, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Neutral
high confidence
Mentioned
$HOWL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (143,199 shares at $0.3100 to $0.3200) and post-sale holdings of 0 shares under a 10b5-1 plan.

02

Market read

This provides incremental sentiment information (insider selling) but is unlikely to drive a fundamental repricing without additional company news.

03

What to watch

Because the sale is indirect and pre-arranged, traders should focus on whether there are concurrent operational catalysts (trial updates, financing, partnerships) rather than the sale itself.

Relevance 2/10Novelty 3/10Timing: after-hours SEC Form 4 filed 2026-07-08

Background

The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc.

Company-level read

Ticker impact

$HOWLNeutralHigh confidence
Context

Werewolf Therapeutics director EVNIN LUKE sold $44.7K of HOWL via a 10b5-1 plan, leaving 0 shares after the trades.

Expected impact

Likely minimal price impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to typical market moves.

Market effects

No clear sector read-through from a small, 10b5-1 director sale.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can still coincide with internal liquidity needs or portfolio rebalancing, so it should not be over-interpreted as bearish.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (HOWL).

  • EVNIN LUKE

    Director who sold HOWL shares via a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou